“HR+/HER2-negative metastatic breast cancer is a highly heterogeneous disease, and this complexity makes it particularly challenging to manage, especially in patients whose disease has already progressed on multiple lines of endocrine therapy,” Hope Rugo, M.D., the director of the Women’s Cancer Program at City of Hope and the trial’s principal investigator, said in a release. “It will be critical that we continue to follow patients for overall survival to better understand the potential impact of [Trodelvy] long-term in this treatment setting.”

---

If you're thinking that the name Hope Rugo sounds familiar...

https://www.cytodyn.com/our-team/scientific-advisory-board